Price: $0.4523
$-0.11
-19.232%
|
Day's High:
| $0.578
| Week Perf:
| -11.31 %
|
Day's Low: |
$ 0.43 |
30 Day Perf: |
15.32 % |
Volume (M): |
37,065 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 16,764 |
52 Wk Avg: |
$0.00 |
Open: |
$0.49 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
18 |
Shares
Outstanding (Millions) |
40 |
Employees |
100 |
Revenues (TTM) (Millions $) |
212 |
Net Income (TTM) (Millions $) |
-143 |
Cash Flow (TTM) (Millions $) |
-78 |
Capital Exp. (TTM) (Millions $) |
26 |
Lucira Health Inc
Lucira Health Inc. is a medical technology company based in the United States that focuses on developing and commercializing innovative technologies for healthcare providers and consumers. The company specializes in the areas of molecular diagnostics, mobile health, and medical devices. The company is best known for its Lucira Check-It COVID-19 At-Home Test Kit, a single-use, molecular test designed to detect the presence of the virus that causes COVID-19.The Lucira Check-It COVID-19 At-Home Test Kit is a portable, quick, and easy-to-use at-home test that helps individuals self-diagnose COVID-19 within 30 minutes. The test is authorized for emergency use in the United States by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) and is the first COVID-19 test that is fully self-contained, enabling users to complete the entire testing process at home without needing to send their samples to a laboratory.Lucira Health Inc. was founded in 2013 and is headquartered in Emeryville, California. The company has partnerships with several healthcare and biotech companies, including Abbott and JSR Life Sciences, to optimize its diagnostic technology and expand its market reach. In addition to its COVID-19 test, the company is also developing other diagnostic products that focus on infectious diseases, cancer, and women's health.
Company Address: 1412 62nd Street Emeryville 94608 CA
Company Phone Number: 350-8071 Stock Exchange / Ticker: NASDAQ LHDX
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Myriad Genetics Inc
r/>Myriad Genetics Inc., a leading molecular diagnostics company, recently announced its participation in an innovative clinical trial that aims to transform the way we monitor minimal residual disease (MRD) across different types of cancer. This collaboration with the National Cancer Center Hospital East in Japan marks a significant milestone in cancer research. By utilizing Myriad's cutting-edge Precise MRD test, researchers aim to evaluate the wide-ranging applicability of MRD monitoring. Financial Performance for Q4 2023: In terms of financial performance, Myriad Genetics Inc. observed improvements in several key areas during the fiscal fourth quarter of 2023. The company reported a decreased loss per share, with $-0.36 per share compared to $-0.52 in the previous year. Additionally, the earnings per share (EPS) improved from $-0.75 per share in the preceding reporting season. The revenue for the fiscal fourth quarter of 2023 increased by 10.574% to $196.60 million from $177.80 million in the same reporting season a year before. Sequentially, the revenue advanced by 2.449% from $191.90 million. Furthermore, the company reported a net shortfall of $-31.200 million, which indicates an improvement compared to the $-42.300 million loss in the same reporting season a year ago.
|
Celldex Therapeutics Inc
Celldex Therapeutics Inc. has proven its strong revenue growth, demonstrating a remarkable 156.107% increase year on year to reach $4.13 million in the most recent fiscal period. Despite an increased deficit per share at $-0.82, the surge in revenue during the fourth quarter of 2023 has positioned Celldex Therapeutics advantageously within the In Vitro and In Vivo Diagnostic Substances sector. Comparatively, its contemporaries in the same sector only experienced average top-line growth of 14.97% during the same period. In the preceding reporting period, Celldex Therapeutics Inc. witnessed a significant improvement in its financials as its deficit per share increased from $-0.81 to $-0.82, while revenue doubled by an impressive 172.314% from $1.52 million. These numbers showcase the company's strong growth trajectory and financial stability.
|
Idexx Laboratories Inc
The financial results of Idexx Laboratories Inc for the fourth quarter of 2023 paint a mixed picture of their performance. On one hand, the company saw a significant increase in revenue of 8.762% to $901.16 million compared to the previous year. This growth is a positive sign of the company's ability to generate more income and attract more customers. Similarly, the increase in EPS by 11.69% to $2.32 per share is also a good indicator of the company's profitability and efficiency in managing costs. These numbers show that Idexx Laboratories Inc is on a solid financial footing and is able to deliver value to its shareholders.
|
Lantheus Holdings Inc
Lantheus Holdings Inc. (LNTH) is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight, and Follow disease in order to deliver better patient outcomes. The company recently reported impressive financial results for its fiscal period ending December 31, 2023. LNTH's net income turned positive, with earnings of $1.45 per share compared to a loss of $1.61 per share the previous year. Although income faded by -22.68% from $1.88 per share in the preceding reporting period, the company?s revenue experienced a significant increase of 34.557% to $354.11 million from $263.17 million in the same period a year before. Sequentially, revenue advanced by 11.023% from $318.95 million. LNTH's top-line growth in the fourth quarter of 2023 is consistent with its peers in the In Vitro and In Vivo Diagnostic Substances sector, which reported an overall 5.74% revenue increase in the same period. It is worth noting that Lantheus Holdings Inc. achieved net profits of $103.38 million in the fiscal period ending December 31, 2023, a significant improvement compared to a net shortfall of $-119.185 million in the same period the previous year. The company also highlighted its improving profit margins, with the net margin rising to 29.19% and the operating margin edging up to 38.83% in the fiscal period ending December 31, 2023.
|
Biomerica Inc
Biomerica Inc, a global provider of advanced medical products, recently reported their financial results for the second quarter of 2024. The company showed a loss of $-0.09 per share, which was an improvement from the loss of $-0.12 per share compared to the same period last year. However, there was a slight increase in shortfall from the previous reporting season, going from $-0.07 per share. Despite the losses, Biomerica Inc saw a revenue growth of 5.742% to $1.57 million in the second quarter of 2024, up from $1.48 million in the same period last year. However, there was a sequential revenue deterioration of -8.523% from the previous quarter. The company's business surge was short of 11.12% compared to the second quarter of 2023, which was seen across the In Vitro and In Vivo Diagnostic Substances sector.
|
Per Share |
Current |
Earnings (TTM) |
-3.58 $ |
Revenues (TTM) |
5.28 $
|
Cash Flow (TTM) |
- |
Cash |
0.99 $
|
Book Value |
1.51 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-3.58 $
|
Revenues (TTM) |
5.28 $ |
Cash Flow (TTM) |
- |
Cash |
0.99 $
|
Book Value |
1.51 $ |
Dividend (TTM) |
0 $ |
|
|
|
|